SEC Form 4 · accession 0001209191-17-013906
Regulus Therapeutics Inc. · RGLS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Timothy Michael Wright
Officer — Chief R & D Officer
Period of report
Feb 15, 2017
Accepted (ET)
Feb 23, 2017 · 5:23 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001505512
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $1.20 | Feb 15, 2017 | A | 32,412 | A | — | Feb 14, 2027 | Common Stock | 32,412 | 32,412 | D |
Explanation of responses
- F125% of the shares vest on January 1, 2018 and the remainder of the shares vest in equal installments on a monthly basis thereafter, such that the option is fully vested on January 1, 2021.